Detected ·
Freenome
——
Freenome (Nasdaq: FRNM) begins trading on Nasdaq today. The early cancer detection company went public through a business combination, gaining capital to advance its multiomic blood-based cancer screening tests, AI/ML-driven platform, and future product launches including SimpleScreen CRC currently under FDA review.
- Website
- www.freenome.com
- linkedin.com/company/freenome
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-27 16:05:58 UTC
- Signal ID
- 95c97d64-d6e4-45ca-82b6-716b605e0cdc
As the API returns it
{
"id": "95c97d64-d6e4-45ca-82b6-716b605e0cdc",
"created_at": "2026-07-27T16:05:58.726106Z",
"company_name": "Freenome",
"company_website_url": "www.freenome.com",
"company_linkedin_url": "https://www.linkedin.com/company/freenome",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Freenome (Nasdaq: FRNM) begins trading on Nasdaq today. The early cancer detection company went public through a business combination, gaining capital to advance its multiomic blood-based cancer screening tests, AI/ML-driven platform, and future product launches including SimpleScreen CRC currently under FDA review.*"
}